Compare Bristol-Myers Squibb Co (BMY) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Synchrony Financial — how do they compare? Bristol-Myers Squibb Co trades at $58.71 (market cap $116.30B), while Synchrony Financial trades at $74.46 (market cap $24.78B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.7× Synchrony Financial's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SYF | |
|---|---|---|
Market Cap | $116.30B | $24.78B |
Sector | Health | Financials |
52-Week High | $62.37 | $88.47 |
52-Week Low | $42.60 | $63.78 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SYF trades at $73.21, up 1.06% today, with a bearish technical signal but strong fundamentals. The stock shows a low P/E of 7.63 and robust profitability with a 24.06% net income margin. Recent earnings beats and a $0.30 dividend highlight operational strength, while analyst consensus is bullish with a $86.38 price target.
Outlook remains positive due to earnings momentum and undervaluation, but risks include economic sensitivity and technical weakness. The stock offers value with upside potential, though investors should monitor loan performance and interest rate impacts on financial results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
